Tumor markers in prostate cancer I: Blood-based markers

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 61-75

  Shariat, Shahrokh F ^a   Semjonow, Axel ^b   Lilja, Hans ^c   Savage, Caroline ^c   Vickers, Andrew J ^c   Bjartell, Anders ^d,e  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BENIGN PROSTATIC HYPERPLASIA ASSOCIATED PROSTATE SPECIFIC ANTIGEN; ENDOGLIN; FINASTERIDE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROTEIN; KALLIKREIN 2; LYSINE; MESSENGER RNA; PROLINE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SERINE; SERINE PROTEINASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

AGE; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; BIOASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CAUSE SPECIFIC SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LINEAR REGRESSION ANALYSIS; METASTASIS; MULTICENTER STUDY (TOPIC); ONCOLOGICAL PARAMETERS; PATIENT MONITORING; PREDICTION; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SPECIFIC ANTIGEN VELOCITY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SPERM; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TISSUE LEVEL;

EID: 79957461212     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.542174     Document Type: Review

References (141)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profi ling. Eur Urol 2007;52:1601-9. (Pubitemid 350052431)
3. Shariat SF, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specifi c antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004;6:58-72.
4. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008;11:112-20. (Pubitemid 351676597)
5. Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003;163:72-84; Discussion 264-6.
6. Winget MD, Baron JA, Spitz MR, Brenner DE, Warzel D, Kincaid H, et al. Development of common data elements: The experience of and recommendations from the early detection research network. Int J Med Inform 2003; 70:41-8. (Pubitemid 36434341)
7. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: Technologies and integrative approaches. Trends Biotechnol 2004;22:411-6. (Pubitemid 38993225)
8. Shariat SF, Karakiewicz PI. Perspectives on prostate cancer biomarkers. Eur Urol 2008;54:8-10.
9. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075-99.
10. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New bloodbased biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008;101:675-83. (Pubitemid 351269995)
11. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative bloodbased biomarkers. Clin Cancer Res 2008;14:3785-91.
12. Shariat SF, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J Urol 2007;178(4 Pt 1):1229-36; Discussion 36-7.
13. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-5. (Pubitemid 36603708)
14. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9. (Pubitemid 46594048)
15. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
16. Vickers AJ, Jang K, Sargent D, Lilja H, Kattan MW. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 2008;112:1862-8. (Pubitemid 351536848)
17. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 2006;26:565-74. (Pubitemid 44728772)
18. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008;8:53.
19. Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 2008;62:314-20.
20. Elkin EB, Vickers AJ, Kattan MW. Primer: Using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol 2006;3:439-48. (Pubitemid 44226921)
21. Ankerst DP, Miyamoto R, Nair PV, Pollock BH, Thompson IM, Parekh DJ. Yearly prostate specifi c antigen and digital rectalexamination fl uctuations in a screened population. J Urol 2009;181:2071-5; Discussion 6.
22. Soletormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W, et al. Biological variation of total prostatespecifi c antigen: A survey of published estimates and consequences for clinical practice. Clin Chem 2005;51:1342-51. (Pubitemid 41060864)
23. Roehrborn CG, Pickens GJ, Carmody T, 3rd. Variability of repeated serum prostate-specifi c antigen (PSA) measurements within less than 90 days in a well-defi ned patient population. Urology 1996;47:59-66. (Pubitemid 26038305)
24. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA, et al. Variation in prostate specifi c antigen results from 2 different assay platforms: Clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171(6 Pt 1):2234-8. (Pubitemid 38625442)
25. Sotelo RJ, Mora KE, Perez LH, Novoa J, Carmona O, De Andrade R, et al. Assay standardization bias: Different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specifi c antigen. Urology 2007;69:1143-6. (Pubitemid 46891573)
26. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specifi c antigen in serum with 5 frequently used assay combinations: An update. Clin Chem 2006;52:59-64. (Pubitemid 43032467)
27. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008;129:952-8.
28. Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, et al. 20-25% lower concentrations of total and free prostate-specifi c antigen (PSA) after calibration of PSA assays to the WHO reference materials-analysis of 1098 patients in four centers. Int J Biol Markers 2009;24:65-9.
29. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specifi c antigen values. Prostate Suppl 1996;7:3-16. (Pubitemid 26412171)
30. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of fi nasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33. (Pubitemid 44288787)
31. Nixon RG, Wener MH, Smith KM, Parson RE, Blase AB, Brawer MK. Day to day changes in free and total PSA: Signifi cance of biological variation. Prostate Cancer Prostatic Dis 1997;1:90-6. (Pubitemid 127537993)
32. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate specifi c antigen levels in serum: An evaluation of day-to-day physiological fl uctuations in a well-defi ned cohort of 24 patients. J Urol 1997;157:2183-90. (Pubitemid 27208668)
33. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002; 35:471-5. (Pubitemid 35284544)
34. Bruun L, Becker C, Hugosson J, Lilja H, Christensson A. Assessment of intra-individual variation in prostate-specifi c antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005;65:216-21. (Pubitemid 41443726)
35. Birkenmeier G, Struck F, Gebhardt R. Clearance mechanism of prostate specifi c antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin. J Urol 1999; 162(3 Pt 1):897-901. (Pubitemid 29436913)
36. Bjork T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, et al. Rapid exponential elimination of free prostate-specifi c antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998;51:57-62.
37. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T, Pettersson K, et al. Signifi cance and metabolism of complexed and noncomplexed prostate specifi c antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999;162:2029-34; Discussion 34-5.
38. Djavan B, Shariat S, Ghawidel K, Guven-Marberger K, Remzi M, Kovarik J, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: Is prostate cancer detection compromised in patients receiving longterm dialysis?. Urology 1999;53:1169-74. (Pubitemid 29264748)
39. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specifi c antigen level or 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
40. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34. (Pubitemid 43898816)
41. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostatespecifi c antigen in men with an initial PSA level of 3.0 ng/ ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
42. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving fi nasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007;25: 3076-81. (Pubitemid 47218054)
43. Berger AP, Volgger H, Rogatsch H, Strohmeyer D, Steiner H, Klocker H, et al. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Prostate 2002;53:241-5. (Pubitemid 35266185)
44. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000;55:791-5. (Pubitemid 30330772)
45. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specifi city with free PSA measurements. JAMA 1997; 277:1452-5. (Pubitemid 27208887)
46. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, et al. Prostate-specifi c antigen-based serial screening may decrease prostate cancer-specifi c mortality. Urology 2006;68:342-7. (Pubitemid 44202546)
47. Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008;18:279-96. (Pubitemid 351489379)
48. Kattan MW. When and how to use informatics tools in caring for urologic patients. Nat Clin Pract Urol 2005; 2:183-90. (Pubitemid 40823139)
49. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confi ned tumors. J Urol 2003;170: 1792-7. (Pubitemid 37254930)
50. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 2007;177:107-12; Discussion 12. (Pubitemid 44879468)
51. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007;25:3582-8. (Pubitemid 47372595)
52. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specifi c antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344(8937): 1594-8. (Pubitemid 24365358)
53. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specifi c antigen for detection of prostatic cancer [see comments]. JAMA 1995;273: 289-94.
54. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specifi c antigen predict long-term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411-6. (Pubitemid 32816360)
55. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specifi c antigen compared with median prostate-specifi c antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316-20. (Pubitemid 43189848)
56. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25: 431-6. (Pubitemid 350002992)
57. Ulmert D, Cronin AM, Bjork T, O'Brien MF, Scardino PT, Eastham JA, et al. Prostate-specifi c antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Med 2008;6:6.
58. Vickers AJ, Ulmert D, Serio AM, Bjork T, Scardino PT, Eastham JA, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. Int J Cancer 2007; 121:2212-7. (Pubitemid 47585600)
59. Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specifi c antigen concentration at age 60 and death or metastasis from prostate cancer: Casecontrol study. BMJ 2010;341:c4521.
60. Lilja H, Ulmert D, Vickers AJ. Prostate-specifi c antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78. (Pubitemid 351430866)
61. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008;53:468-77. (Pubitemid 351179007)
62. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 2007;3:449-61. (Pubitemid 47260286)
63. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-specifi c antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
64. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specifi c antigen levels in men with and without prostate disease [see comments]. J Am Med Assoc 1992;267:2215-20.
65. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specifi c antigen velocity. Eur Urol 2007;52:1044-50.
66. Smith DS, Catalona WJ. Rate of change in serum prostate specifi c antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7. (Pubitemid 24283458)
67. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, et al. Prostate-specifi c antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specifi c antigen velocity. Urology 1995;45:591-6.
68. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specifi c antigen velocity at low prostate-specifi c antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM). Urology 2004;63:309-13; Discussion 13-5. (Pubitemid 38234425)
69. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006;49:460-5; Discussion 5. (Pubitemid 43259552)
70. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, et al. Prostate-specifi c antigen velocity and pro state cancer gleason grade and stage. Cancer 2007;109: 1689-95. (Pubitemid 46595706)
71. Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, et al. Long-term prediction of prostate cancer: Prostate-specifi c antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26: 835-41. (Pubitemid 351398073)
72. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351: 125-35.
73. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294: 440-7. (Pubitemid 41124176)
74. Patel DA, Presti JC, Jr., McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005;23:6157-62.
75. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate-specifi c antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7. (Pubitemid 44680903)
76. National Comprehensive Cancer Network [Internet]. National Comprehensive; 2004. Available from: http://www. nccn.org/professionals/physician-gls/PDF/ prostate- detection.pdf.
77. V ickers A, Tangen C, Till C, Lilja H, Thompson I. An empirical evaluation of the national cancer center network guidelines on prostate specifi c antigen velocity in prostate cancer detection. J Urol 2010;183:e771.
78. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Prostate-specifi c antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99: 526-32. (Pubitemid 47073555)
79. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Jr., Yossepowitch O, Vickers AJ, et al. Prostate cancer-specifi c mortality after radical prostatectomy for patients treated in the prostate-specifi c antigen era. J Clin Oncol 2009;27: 4300-5.
80. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate-specifi c antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-7.
81. Frank O'Brien M, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, et al. Evaluation of prediagnostic prostatespecifi c antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer Epub 2010 Jul 23.
82. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. The association between total prostate specifi c antigen concentration and prostate specifi c antigen velocity. J Urol 2007;177: 1298-302; Discussion 301-2. (Pubitemid 46436021)
83. Lilja H. Signifi cance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. [Review]. Urol Clin North Am 1993;20:681-6. (Pubitemid 24141161)
84. Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Preoperative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Eur Urol 2006;49:293-302. (Pubitemid 43197868)
85. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specifi c PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60. (Pubitemid 30495578)
86. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specifi c antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279:1542-7. (Pubitemid 28233009)
87. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specifi c antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12. (Pubitemid 27525562)
88. Canto EI, Singh H, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specifi c antigen for prostate cancer detection. J Urol 2004;172:900-4. (Pubitemid 39096417)
89. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, et al. Percent free prostate specifi c antigen is not an independent predictor of organ confi nement or prostate specifi c antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002;167:1306-9. (Pubitemid 34132076)
90. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specifi c antigen in serum is becoming more complex. Urology 2002;59:797-802. (Pubitemid 34522163)
91. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specifi c antigen is a more specifi c serum marker of prostate cancer. Cancer Res 2001;61:6958-63. (Pubitemid 32896525)
92. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: Preliminary analysis. Urology 2003;61:274-6. (Pubitemid 36206515)
93. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-prostate specifi c antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specifi c antigen. J Urol 2004; 171(6 Pt 1):2239-44. (Pubitemid 38625443)
94. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, et al. Serum pro prostate specifi c antigen improves cancer detection compared to free and complexed prostate specifi c antigen in men with prostate specifi c antigen 2 to 4 ng/ml. J Urol 2003;170(6 Pt 1): 2181-5. (Pubitemid 37413952)
95. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, et al. A [-2]proPSA-based artifi cial neural network signifi cantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69:198-207.
96. Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, et al. Pro-prostate-specifi c antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009;15:7316-21.
97. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C. Pre-analytical in-vitro stability of [?2]proPSA in blood and serum. Clin Biochem 2010;43:926-8.
98. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, et al. "BPSA," a specifi c molecular form of free prostate-specifi c antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55:41-5. (Pubitemid 30050755)
99. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004;63:905-10; Discussion 10-1. (Pubitemid 38596676)
100. Stephan C, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, et al. Benign prostatic hyperplasia-associated free prostate-specifi c antigen improves detection of prostate cancer in an artifi cial neural network. Urology 2009;74: 873-7.
101. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009;69:886-94.
102. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
103. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J Clin Oncol 2010;28:2493-8.
104. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specifi c antigen: Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010;116:2612-20.
105. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232-9.
106. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. Br J Cancer Epub 2010 Jul 27.
107. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204. (Pubitemid 32458158)
108. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specifi c antigen. J Clin Oncol 2000;18:1036-42. (Pubitemid 30123780)
109. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specifi c antigen in serum from a population of men with prostate-specifi c antigen levels 3.0 ng/mL or greater. Urology 2000;55:694-9.
110. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000; 163:311-6.
111. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confi ned from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9. (Pubitemid 32937805)
112. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360-5. (Pubitemid 28399898)
113. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lummen G, Wernli M, et al. The importance of human glandular kallikrein and its correlation with different prostate specifi c antigen serum forms in the detection of prostate carcinoma. Cancer 1998;83:2540-7. (Pubitemid 29019575)
114. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, et al. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specifi c antigen, human kallikrein 2, and prostate-specifi c membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004;10: 5808-14. (Pubitemid 39180959)
115. Duffy MJ. Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 2002;30:207-10.
116. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009;55:1124-33.
117. Steuber T, Vickers A, Haese A, Kattan MW, Eastham JA, Scardino PT, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007;120:1499-504. (Pubitemid 46355384)
118. Hienert G, Kirchheimer JC, Pfl uger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988;140:1466-9.
119. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999;39:123-9. (Pubitemid 29194284)
120. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55. (Pubitemid 350002982)
121. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64. (Pubitemid 32538195)
122. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum Pathol 1993;24:4-9. (Pubitemid 23046665)
123. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, et al. Association of pre-and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-9. (Pubitemid 38375558)
124. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001;92: 2985-92. (Pubitemid 33136192)
125. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995;1:282-4.
126. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specifi c protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58: 4640-5. (Pubitemid 28480629)
127. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159:2159-65. (Pubitemid 33104270)
128. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-6. (Pubitemid 38961893)
129. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-6. (Pubitemid 30482107)
130. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027-30.
131. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-75. (Pubitemid 34556377)
132. Fujita K, Ewing CM, Chan DY, Mangold LA, Partin AW, Isaacs WB, et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 2009;124:664-9.
133. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 2008;14:1418-22. (Pubitemid 351413924)
134. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008;14:3362-6.
135. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-15. (Pubitemid 34017290)
136. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655-63. (Pubitemid 41079804)
137. Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recur rence after radical prostatectomy. J Clin Oncol 2008;26:1526-31.
138. Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, et al. Detection of clinically signifi cant, occult prostate cancer metastases in lymph nodes using a splice variant-specifi c rt-PCR assay for human glandular kallikrein. J Clin Oncol 2003;21:1223-31. (Pubitemid 46606397)
139. Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: A twentyfi rst century tower of Babel. Cancer 2008;113:966-74.
140. Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006;3:658-67. (Pubitemid 44843124)
141. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360: 1320-8.